Replies to post #86178 on Biotech Values

[kris_kade]

FWIW, I expect MNTA to re-base itself again around 9.50 area until next Q call. It's very unlikely we will get approval by end of this year when especially FDA has yet to fully disclose their report on heprain supply chain safety.